30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Johnson & Johnson

Orthopaedic sales $2,385MM, +49% (U.S. $1,274MM, +46%, ex-U.S. $1,111MM, +52%)

  • Hips +4% (U.S. +5%, ex-U.S. +4%)
  • Knees +2% (U.S. +3%, ex-U.S. +1%)
  • Trauma +4% (U.S. +2%, ex-U.S. +7%)
  • Sports Medicine +7% (U.S. +9%, ex-U.S. +4%)
  • Spine -2% (U.S. -7%, ex-U.S. +6%)

Excluding Synthes/trauma divestiture, growth +3% (U.S. +3%, ex-U.S. +4%)

Overall worldwide pricing -1%

  • U.S. hip pricing -3.5%, mix +1.5%
  • U.S. knee pricing -1%, mix +1.5%
  • U.S. spine pricing -3%, mix +2.5%
  • U.S. primary stem platform sales strong, partially offset by price pressure
  • Favorable initial response to Attune knee launch
  • Trauma growth fueled by Europe and emerging markets, notably China
  • Strong spine growth in Asia Pacific, Canada, Latin America
  • Consolidated external manufacturing/materials suppliers by ~1/3 over the last 3 years